JUN 27, 2014 12:00 AM PDT

Orgenesis will use grant money to do further research on cures for diabetes and other diseases.

WRITTEN BY: Ilene Schneider
Orgenesis Inc. a leader in the emerging fields of cellular therapy and regenerative medicine, announced that it raised $1.5 million via a senior secured term loan facility.

Based in Israel, Orgenesis is out to solve Type 1 Diabetes as we know it. The funding will help to ramp up its ground breaking research on cellular trans-differentiation and put the company on the fast track towards human trials. Cellular trans-differentiation is the breakthrough innovation that works to restore a patient's natural insulin production and blood sugar regulation by enabling the patient's own liver cells create insulin.

"This infusion of funding allows us to aggressively move forward with the development of new medical technologies and cell therapies for the treatment of diabetes," said Vered Caplan, chairperson and CEO of Orgenesis. "The focus will immediately be on our Belgium subsidiary, Orgenesis SPRL, where all the funds will be used to advance our research on cellular trans-differentiation as a potential curative treatment for serious diseases such as type 1 diabetes and quicken our pace toward human trials."

The financing also opens the door for future funding and grants by making Orgenesis eligible to tap into additional government financing and grant opportunities in Europe.

Cellular trans-differentiation has the potential to release patients from constant monitoring and insulin-dependence while eliminating the need for immunosuppressive or immunomodulatory therapy, effectively putting an end to diabetes as it is known today.

Orgenesis SPRL was established and registered in 2013 as a subsidiary in Belgium to complete process development and enable product manufacturing of cells to be used for clinical trials in Europe. The incorporation of Orgenesis SPRL follows a partnership established in May 2013 with ATMI, Inc, which was acquired by Pall Technologies, to leverage the highly innovative Integrity® Xpansion™ disposable bioreactors, which became a major component in Orgenesis' cell culture product manufacturing. Prior to establishing Orgenesis SPRL, Orgenesis began working with key CMOs (contract manufacturing organizations) in Belgium's Walloon region in order to develop a commercially-scalable manufacturing process. The Walloon region has become a central hub to innovative companies developing new technologies for cell therapy.

A development stage company that is committed to curing Type 1 diabetes, the company is developing a novel technology that combines cellular therapy and regenerative medicine. Through trans-differentiation, the company has pioneered an approach that turns an insulin-dependent patient's own liver cells into functional insulin producing cells. Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JAN 05, 2021
Immunology
Immune Imbalances Dictate COVID Symptom Severity
JAN 05, 2021
Immune Imbalances Dictate COVID Symptom Severity
COVID symptoms. “As it is often the case for pathogenic infections, the host immune system is a key player in vira ...
JAN 04, 2021
Cannabis Sciences
How Does Cannabis Affect the Liver?
JAN 04, 2021
How Does Cannabis Affect the Liver?
As research on cannabis emerges, what we know about how it interacts with the liver is becoming more and more complex. A ...
JAN 15, 2021
Microbiology
Enterovirus Images May Pave the Way to Edible Vaccines
JAN 15, 2021
Enterovirus Images May Pave the Way to Edible Vaccines
Most adenoviruses infect the respiratory system. But there are variants of these viruses that infect the gastrointestina ...
JAN 25, 2021
Microbiology
CrAssphages and the Manipulation of the Microbiome
JAN 25, 2021
CrAssphages and the Manipulation of the Microbiome
The advancement of genetic and computational tools has given us so much new information its opened up new research field ...
JAN 25, 2021
Cell & Molecular Biology
Beyond Organoids to a Better Research Model
JAN 25, 2021
Beyond Organoids to a Better Research Model
For many years, scientists have relied on cells that grow in dishes and animal models to learn more about human diseases ...
FEB 10, 2021
Genetics & Genomics
The Evolution of Snake Venom From Predation to Protection
FEB 10, 2021
The Evolution of Snake Venom From Predation to Protection
The venom of some spitting snakes has evolved to cause more pain to mammals, a defense mechanism likely meant to fend of ...
Loading Comments...